Sort
4,870 grants matching “glp 1”
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$1,262,498Elias Sayour · University Of Florida · R01 · FY2022 · FD
Development of Anti-necrosis Drug for Acute Brain Injury
$1,261,272Junying Yuan · Harvard Medical School · U01 · FY2006 · NS
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)
$1,259,042Raja G Khalifah · Praetego, Inc. · R44 · FY2022 · AG
Purpose: To award Task Order 75N95020F00002 (GLP Interaction Safety Studies in Rats and Dogs) under IDIQ No. HHSN271201800019I.
$1,256,044Laura Evans · Sri International · N01 · FY2020 · DA
Protective Mechanisms In Cerebral Ischemia
$1,255,421John Hallenbeck · National Institute Of Neurological Disorders And Stroke · ZIA · FY2012 · NS
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
$1,253,534Simon Petersen-Jones · Michigan State University · R24 · FY2018 · EY
Targeting Therapeutics for Accelerated Bone Fracture Repair
$1,252,939Stewart Andrew Low · Novosteo, Inc. · R44 · FY2020 · DE
Development of a novel adjuvant for vaccine sparing
$1,250,865Sara Lustigman · New York Blood Center · R01 · FY2016 · AI
Glial Progenitor Cells for Treatment of ALS
$1,249,174Linda L Kelley · University Of Utah · U01 · FY2010 · NS
Development of a novel adjuvant for vaccine sparing
$1,248,398Sara Lustigman · New York Blood Center · R01 · FY2017 · AI
Development of an Innovative Material for Transcatheter Peripheral Embolization
$1,247,814Ehsan Jabbarzadeh · Obsidio, Inc. · R44 · FY2022 · HL
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
$1,246,866Harshini Neelakantan · Ridgeline Therapeutics, Llc · U44 · FY2022 · AG
IND-Enabling Studies of ZB716, an Orally Bioavailable SERD
$1,246,181Guangdi Wang · Zenopharm, Llc · R44 · FY2019 · CA
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)
$1,246,076Raja G Khalifah · Praetego, Inc. · R44 · FY2023 · AG
Novel Therapeutic Agents to Reverse Opioid Overdose
$1,245,607Xinhua Li · Clear Scientific, Llc · R44 · FY2022 · DA
Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease
$1,244,790Daniel Chelsky · Circumvent Pharmaceuticals, Inc. · R44 · FY2025 · NS
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
$1,244,665David S Perlin · Rbhs-New Jersey Medical School · R01 · FY2018 · AI
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,243,462Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2013 · EY
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
$1,242,959Harshini Neelakantan · Ridgeline Therapeutics, Llc · U44 · FY2023 · AG
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
$1,242,150Mone Zaidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AG
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients
$1,239,748Christian Young · Allander Biotechnologies, Inc. · SB1 · FY2023 · DE
Antibody immunotherapeutics for biodefense against Lassa virus
$1,238,702Robert F Garry · Tulane University Of Louisiana · R01 · FY2016 · AI
Novel SCD1 inhibitors for treatment of cancer
$1,236,819John A Copland · Modulation Therapeutics, Inc. · R42 · FY2019 · CA
First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
$1,233,852Christian Young · Allander Biotechnologies, Inc. · R44 · FY2025 · CA
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
$1,230,830Keith Wycoff · Planet Biotechnology, Inc. · R01 · FY2012 · AI